Gold Track worked with Phagomed on sharpened their storytelling through streamlining of their product offerings, data, clinical utility, Phase 1, 2 and 3 clinical strategies, as well as mapping use of proceeds for the next funding round. Gold Track supported Phagomed with investor outreach towards their series A, which transformed into a preclinical acquisition by BioNTech in Q4 2021.